Therapy of advanced breast cancer for patients with hormone receptor-positive / HER2-negative and HER2-positive tumors is changing real life. First results from the prospective, national research platform OPAL for patients with advanced breast cancer in Germany. 13. Dezember 2019 E. Stickeler, N. Harbeck, M. Thill, A. Nusch, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, M. Zahn, A. Welt, A. Wöckel, T. Decker, OPAL study group, 2019. Cancer Res February 15 2020 (80) (4 Supplement) P2-17-01; DOI: 10.1158/1538-7445.SABCS19-P2-17-01 Negative impact of disease progression on quality of life of patients with advanced breast cancer – Data from the TMK/MaLife project. Marschner N, Zacharias S, Welt A, Decker T, Nusch A, Kruggel L, Jänicke M, for the TMK Registry group, 2019. The Breast 48 (suppl2), 71. Weiterlesen Palbociclib in combination with anastrozole or exemestane for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany. Interim results of the INGE-B phase 2 trial. M. Welslau, N. Marschner, U. Söling, C. Brucker, O.J. Stoetzer, J. Meiler, P.Wimberger, S.Dörfel, J.Sahlmann, L.Houet, C.Vannier, K.Potthoff, 2019. Cancer Res February 15 2020 (80)… Weiterlesen